Smith & Nephew (LON:SN) Stock Passes Above 200 Day Moving Average – Here’s Why

Posted by Michelle Swanson on Apr 5th, 2025

Smith & Nephew plc (LON:SN – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,049.11 ($13.53) and traded as high as GBX 1,080.50 ($13.94). Smith & Nephew shares last traded at GBX 1,075 ($13.87), with a volume of 1,097,949 shares.

Analyst Ratings Changes

Separately, JPMorgan Chase & Co. reiterated an “overweight” rating and set a GBX 1,180 ($15.22) price objective on shares of Smith & Nephew in a research report on Tuesday, January 14th.

Read Our Latest Research Report on SN

Smith & Nephew Trading Down 4.4 %

The company has a fifty day moving average of GBX 1,075.40 and a 200-day moving average of GBX 1,048.29. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The firm has a market capitalization of £11.30 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Smith & Nephew Increases Dividend

The business also recently declared a dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Thursday, March 27th will be given a $0.23 dividend. The ex-dividend date of this dividend is Thursday, March 27th. This represents a dividend yield of 1.61%. This is a boost from Smith & Nephew’s previous dividend of $0.14. Smith & Nephew’s payout ratio is currently 104.41%.

Insiders Place Their Bets

In related news, insider Sybella Stanley purchased 3,810 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of GBX 1,101 ($14.20) per share, for a total transaction of £41,948.10 ($54,112.62). Company insiders own 0.19% of the company’s stock.

Smith & Nephew Company Profile

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.